Connect with us
Information

Australia
North America
World

Investing News NetworkYour trusted source for investing success

North America
Australia
World
My INN

Private Placements

Reports & Guides
- Market Outlook Reports
- Investing Guides

Precious Metals
Battery Metals
Base Metals
Energy
Critical Metals

Company Profiles Market

Company Profiles News

Company Profiles Stocks

Company Profiles Market
Company Profiles News
Company Profiles Stocks

BELLUS Health Inc.

TSX:BLU

Featured Articles and Interviews

More Featured Articles and Inverviews

Press Releases

May 12, 2023

BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights

Apr 26, 2023

BELLUS Health Announces Meeting Updates

Nov 14, 2019

BELLUS Health Reports Q3 Financial Results

More Press Releases

BELLUS Health Inc is a clinical-stage biopharmaceutical development company advancing novel therapeutics for conditions with a high unmet medical need, including BLU-5937, P2X3 antagonist that has the potential to be a best-in-class therapeutic for chronic cough. The company operates in one business segment namely, the development of drug candidates for health solutions.

Go Deeper

AI Powered

Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 Small-cap Biotech Stocks (Updated January 2025)

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. , BELLUS Health Inc , Prometheus Biosciences, Inc. , Univar Solutions Inc.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. , BELLUS Health Inc , Prometheus Biosciences, Inc. , Univar Solutions Inc.

Interactive Chart

Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.